Clinical  ||| S:0 E:9 ||| JJ
roundtable  ||| S:9 E:20 ||| JJ
monograph ||| S:20 E:29 ||| NN
:  ||| S:29 E:31 ||| :
Emerging  ||| S:31 E:40 ||| VBG
treatment  ||| S:40 E:50 ||| NN
options  ||| S:50 E:58 ||| NNS
for  ||| S:58 E:62 ||| IN
TKI-resistant  ||| S:62 E:76 ||| JJ
chronic  ||| S:76 E:84 ||| JJ
myelogenous  ||| S:84 E:96 ||| NNS
leukemia  ||| S:96 E:105 ||| VBP
The  ||| S:105 E:109 ||| DT
development  ||| S:109 E:121 ||| NN
of  ||| S:121 E:124 ||| IN
tyrosine  ||| S:124 E:133 ||| FW
kinase  ||| S:133 E:140 ||| FW
inhibitors  ||| S:140 E:151 ||| FW
( ||| S:151 E:152 ||| -LRB-
TKIs ||| S:152 E:156 ||| NNP
)  ||| S:156 E:158 ||| -RRB-
that  ||| S:158 E:163 ||| WDT
inhibit  ||| S:163 E:171 ||| VBP
signaling  ||| S:171 E:181 ||| VBG
of  ||| S:181 E:184 ||| IN
the  ||| S:184 E:188 ||| DT
constitutive  ||| S:188 E:201 ||| JJ
BCR-ABL  ||| S:201 E:209 ||| JJ
protein  ||| S:209 E:217 ||| NN
revolutionized  ||| S:217 E:232 ||| VBD
the  ||| S:232 E:236 ||| DT
treatment  ||| S:236 E:246 ||| NN
of  ||| S:246 E:249 ||| IN
chronic  ||| S:249 E:257 ||| JJ
myelogenous  ||| S:257 E:269 ||| JJ
leukemia  ||| S:269 E:278 ||| NN
( ||| S:278 E:279 ||| -LRB-
CML ||| S:279 E:282 ||| NNP
) ||| S:282 E:283 ||| -RRB-
.  ||| S:283 E:285 ||| .
These  ||| S:285 E:291 ||| DT
agents  ||| S:291 E:298 ||| NNS
have  ||| S:298 E:303 ||| VBP
dramatically  ||| S:303 E:316 ||| RB
changed  ||| S:316 E:324 ||| VBN
the  ||| S:324 E:328 ||| DT
treatment  ||| S:328 E:338 ||| NN
landscape  ||| S:338 E:348 ||| NN
for  ||| S:348 E:352 ||| IN
CML ||| S:352 E:355 ||| NNP
,  ||| S:355 E:357 ||| ,
shifting  ||| S:357 E:366 ||| VBG
the  ||| S:366 E:370 ||| DT
use  ||| S:370 E:374 ||| NN
of  ||| S:374 E:377 ||| IN
allogeneic  ||| S:377 E:388 ||| JJ
stem  ||| S:388 E:393 ||| NN
cell  ||| S:393 E:398 ||| NN
transplantation  ||| S:398 E:414 ||| NN
to  ||| S:414 E:417 ||| TO
selected  ||| S:417 E:426 ||| JJ
patients  ||| S:426 E:435 ||| NNS
in  ||| S:435 E:438 ||| IN
the  ||| S:438 E:442 ||| DT
salvage  ||| S:442 E:450 ||| NN
setting ||| S:450 E:457 ||| NN
.  ||| S:457 E:459 ||| .
Four  ||| S:459 E:464 ||| CD
BCR-ABL  ||| S:464 E:472 ||| JJ
TKIs  ||| S:472 E:477 ||| NNS
are  ||| S:477 E:481 ||| VBP
now  ||| S:481 E:485 ||| RB
commercially  ||| S:485 E:498 ||| RB
available  ||| S:498 E:508 ||| JJ
for  ||| S:508 E:512 ||| IN
the  ||| S:512 E:516 ||| DT
treatment  ||| S:516 E:526 ||| NN
of  ||| S:526 E:529 ||| IN
CML ||| S:529 E:532 ||| NNP
:  ||| S:532 E:534 ||| :
the  ||| S:534 E:538 ||| DT
first-generation  ||| S:538 E:555 ||| JJ
TKI  ||| S:555 E:559 ||| NNP
imatinib ||| S:559 E:567 ||| NN
,  ||| S:567 E:569 ||| ,
and  ||| S:569 E:573 ||| CC
the  ||| S:573 E:577 ||| DT
second-generation  ||| S:577 E:595 ||| JJ
TKIs  ||| S:595 E:600 ||| JJ
dasatinib ||| S:600 E:609 ||| NN
,  ||| S:609 E:611 ||| ,
nilotinib ||| S:611 E:620 ||| NN
,  ||| S:620 E:622 ||| ,
and  ||| S:622 E:626 ||| CC
bosutinib ||| S:626 E:635 ||| NN
.  ||| S:635 E:637 ||| .
Continuous  ||| S:637 E:648 ||| JJ
treatment  ||| S:648 E:658 ||| NN
with  ||| S:658 E:663 ||| IN
these  ||| S:663 E:669 ||| DT
agents  ||| S:669 E:676 ||| NNS
induces  ||| S:676 E:684 ||| VBZ
durable  ||| S:684 E:692 ||| JJ
responses  ||| S:692 E:702 ||| NNS
in  ||| S:702 E:705 ||| IN
a  ||| S:705 E:707 ||| DT
high  ||| S:707 E:712 ||| JJ
proportion  ||| S:712 E:723 ||| NN
of  ||| S:723 E:726 ||| IN
patients  ||| S:726 E:735 ||| NNS
with  ||| S:735 E:740 ||| IN
chronic-phase  ||| S:740 E:754 ||| NNP
CML ||| S:754 E:757 ||| NNP
.  ||| S:757 E:759 ||| .
Research  ||| S:759 E:768 ||| NNP
is  ||| S:768 E:771 ||| VBZ
focused  ||| S:771 E:779 ||| VBN
on  ||| S:779 E:782 ||| IN
identifying  ||| S:782 E:794 ||| NNS
which  ||| S:794 E:800 ||| WDT
patients  ||| S:800 E:809 ||| NNS
can  ||| S:809 E:813 ||| MD
discontinue  ||| S:813 E:825 ||| VB
therapy  ||| S:825 E:833 ||| NN
without  ||| S:833 E:841 ||| IN
a  ||| S:841 E:843 ||| DT
recurrence  ||| S:843 E:854 ||| NN
of  ||| S:854 E:857 ||| IN
disease ||| S:857 E:864 ||| NN
.  ||| S:864 E:866 ||| .
For  ||| S:866 E:870 ||| IN
the  ||| S:870 E:874 ||| DT
group  ||| S:874 E:880 ||| NN
of  ||| S:880 E:883 ||| IN
patients  ||| S:883 E:892 ||| NNS
with  ||| S:892 E:897 ||| IN
resistance  ||| S:897 E:908 ||| NN
to  ||| S:908 E:911 ||| TO
TKIs ||| S:911 E:915 ||| JJ
,  ||| S:915 E:917 ||| ,
multiple  ||| S:917 E:926 ||| JJ
alternative  ||| S:926 E:938 ||| NN
therapies  ||| S:938 E:948 ||| NNS
are  ||| S:948 E:952 ||| VBP
being  ||| S:952 E:958 ||| VBG
evaluated ||| S:958 E:967 ||| VBN
.  ||| S:967 E:969 ||| .
The  ||| S:969 E:973 ||| DT
third-generation  ||| S:973 E:990 ||| JJ
TKI  ||| S:990 E:994 ||| NNP
ponatinib  ||| S:994 E:1004 ||| NN
is  ||| S:1004 E:1007 ||| VBZ
a  ||| S:1007 E:1009 ||| DT
BCR-ABL  ||| S:1009 E:1017 ||| JJ
inhibitor  ||| S:1017 E:1027 ||| NN
that  ||| S:1027 E:1032 ||| WDT
has  ||| S:1032 E:1036 ||| VBZ
demonstrated  ||| S:1036 E:1049 ||| VBN
significant  ||| S:1049 E:1061 ||| JJ
activity ||| S:1061 E:1069 ||| NN
,  ||| S:1069 E:1071 ||| ,
including  ||| S:1071 E:1081 ||| VBG
in  ||| S:1081 E:1084 ||| IN
patients  ||| S:1084 E:1093 ||| NNS
with  ||| S:1093 E:1098 ||| IN
the  ||| S:1098 E:1102 ||| DT
TKI  ||| S:1102 E:1106 ||| NNP
resistance  ||| S:1106 E:1117 ||| NN
mutation  ||| S:1117 E:1126 ||| NN
T315I ||| S:1126 E:1131 ||| NN
.  ||| S:1131 E:1133 ||| .
The  ||| S:1133 E:1137 ||| DT
homoharringtonine  ||| S:1137 E:1155 ||| JJ
derivative  ||| S:1155 E:1166 ||| JJ
omacetaxine  ||| S:1166 E:1178 ||| JJ
mepesuccinate ||| S:1178 E:1191 ||| NN
,  ||| S:1191 E:1193 ||| ,
which  ||| S:1193 E:1199 ||| WDT
inhibits  ||| S:1199 E:1208 ||| VBZ
protein  ||| S:1208 E:1216 ||| JJ
synthesis ||| S:1216 E:1225 ||| NN
,  ||| S:1225 E:1227 ||| ,
has  ||| S:1227 E:1231 ||| VBZ
also  ||| S:1231 E:1236 ||| RB
demonstrated  ||| S:1236 E:1249 ||| VBN
clinical  ||| S:1249 E:1258 ||| JJ
activity  ||| S:1258 E:1267 ||| NN
in  ||| S:1267 E:1270 ||| IN
CML ||| S:1270 E:1273 ||| NNP
,  ||| S:1273 E:1275 ||| ,
including  ||| S:1275 E:1285 ||| VBG
in  ||| S:1285 E:1288 ||| IN
patients  ||| S:1288 E:1297 ||| NNS
with  ||| S:1297 E:1302 ||| IN
TKI  ||| S:1302 E:1306 ||| NNP
resistance  ||| S:1306 E:1317 ||| NN
due  ||| S:1317 E:1321 ||| JJ
to  ||| S:1321 E:1324 ||| TO
T315I  ||| S:1324 E:1330 ||| CD
and  ||| S:1330 E:1334 ||| CC
in  ||| S:1334 E:1337 ||| IN
patients  ||| S:1337 E:1346 ||| NNS
who  ||| S:1346 E:1350 ||| WP
have  ||| S:1350 E:1355 ||| VBP
TKI  ||| S:1355 E:1359 ||| JJ
resistance  ||| S:1359 E:1370 ||| NN
despite  ||| S:1370 E:1378 ||| IN
no  ||| S:1378 E:1381 ||| DT
evidence  ||| S:1381 E:1390 ||| NN
of  ||| S:1390 E:1393 ||| IN
ABL  ||| S:1393 E:1397 ||| NNP
mutations ||| S:1397 E:1406 ||| NNS
.  ||| S:1406 E:1408 ||| .
It  ||| S:1408 E:1411 ||| PRP
is  ||| S:1411 E:1414 ||| VBZ
essential  ||| S:1414 E:1424 ||| JJ
that  ||| S:1424 E:1429 ||| IN
clinicians  ||| S:1429 E:1440 ||| RB
implement  ||| S:1440 E:1450 ||| VB
these  ||| S:1450 E:1456 ||| DT
new  ||| S:1456 E:1460 ||| JJ
agents  ||| S:1460 E:1467 ||| NNS
with  ||| S:1467 E:1472 ||| IN
care  ||| S:1472 E:1477 ||| NN
and  ||| S:1477 E:1481 ||| CC
change  ||| S:1481 E:1488 ||| NN
therapies  ||| S:1488 E:1498 ||| NNS
only  ||| S:1498 E:1503 ||| RB
when  ||| S:1503 E:1508 ||| WRB
appropriate  ||| S:1508 E:1520 ||| JJ
in  ||| S:1520 E:1523 ||| IN
order  ||| S:1523 E:1529 ||| NN
to  ||| S:1529 E:1532 ||| TO
preserve  ||| S:1532 E:1541 ||| VB
as  ||| S:1541 E:1544 ||| IN
many  ||| S:1544 E:1549 ||| JJ
options  ||| S:1549 E:1557 ||| NNS
as  ||| S:1557 E:1560 ||| IN
possible  ||| S:1560 E:1569 ||| JJ
for  ||| S:1569 E:1573 ||| IN
future  ||| S:1573 E:1580 ||| JJ
use  ||| S:1580 E:1584 ||| NN
if  ||| S:1584 E:1587 ||| IN
needed ||| S:1587 E:1593 ||| VBN
.  ||| S:1593 E:1595 ||| .
